Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 12, 2018 - Issue 12
Submit an article Journal homepage
72
Views
16
CrossRef citations to date
0
Altmetric
Original Research

An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens

Mohamed El KassasEndemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, EgyptCorrespondence[email protected]
View further author information
,
Mohamed AlboraieDepartment of Internal Medicine, Al-Azhar University, Cairo, EgyptView further author information
,
Dalia OmranEndemic Medicine and Hepato-Gastroenterology Department, Faculty of Medicine, Cairo University, Cairo, EgyptView further author information
,
Mohamed SalaheldinTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptView further author information
,
Mohamed Naguib WifiInternal Medicine Department, Faculty of Medicine, Cairo University, Cairo, EgyptView further author information
,
Mohamed ElBadryTropical Medicine and Gastroenterology Department, Faculty of Medicine, Aswan University, Aswan, EgyptView further author information
,
Adel El TahanNew Cairo Viral Hepatitis Treatment Unit, Cairo, EgyptView further author information
,
Sameera EzzatEpidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Shebin Elkom, EgyptView further author information
,
Enass MoazEpidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Shebin Elkom, EgyptView further author information
,
Amir M FaridTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptView further author information
,
Heba OmarEndemic Medicine and Hepato-Gastroenterology Department, Faculty of Medicine, Cairo University, Cairo, EgyptORCID Iconhttp://orcid.org/0000-0002-9707-1141View further author information
ORCID Icon,
Mahmoud AbouelkhairEndemic Medicine and Hepato-Gastroenterology Department, Faculty of Medicine, Cairo University, Cairo, EgyptView further author information
,
Shimaa AfifyNational Hepatology and Tropical Medicine Research Institute, Cairo, EgyptView further author information
,
Kadry ElsaeedInternal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptView further author information
,
Yehia ShazlyInternal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptView further author information
,
Wahid DossEndemic Medicine and Hepato-Gastroenterology Department, Faculty of Medicine, Cairo University, Cairo, EgyptView further author information
&
Gamal EsmatEndemic Medicine and Hepato-Gastroenterology Department, Faculty of Medicine, Cairo University, Cairo, EgyptView further author information
 show all
Pages 1265-1272 | Received 02 Jan 2018, Accepted 09 May 2018, Published online: 24 May 2018

References

  • Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342.
  • El Kassas M, Elbaz T, Elsharkawy A, et al. HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Rev Anti Infect Ther. 2018;16(4):345–350.
  • Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.
  • Asselah T. Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol. 2014;61(2):435–438.
  • Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63(3):581–585.
  • El-Akel W, El-Sayed M, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2017;24(4):262–267.
  • Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18378 patients in Egypt. Aliment Pharmacol Ther. 2017:1–11. doi: 10.1111/apt.14428
  • Eletreby R, Elakel W, Said M, et al. Real life Egyptian experience of efficacy and safety of simeprevir/sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017;37(4):534–541.
  • Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: a review. Expert Opin Drug Saf. 2016 Dec;15(12):1643–1652.
  • El Kassas M, Elbaz T, Hafez E. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016 Dec;15(12):1643–1652.
  • Bonnard P, Elsharkawy A, Zalata K, et al. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt. J Viral Hepat. 2015;22:245–253.
  • Elsharkawy A, Eletreby R, Fouad R, et al. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Rev Gastroenterol Hepatol. 2017;11(8):773–778.
  • Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62(5):1040–1046.
  • Elsharkawy A, Fouad R, El Akel W, et al. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Aliment Pharmacol Ther. 2017;45(5):681–687.
  • El Raziky M, Gamil M, Hammad R, et al. Treatment of hepatitis C genotype 4 patients with simeprevir and sofosbuvir: preliminary results from a phase IIa, partially randomised, open-label trial conducted in Egypt (OSIRIS). Abstract ID: 1163. OSIRIS poster, presented at the Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases.2015.
  • Willemse SB, Baak LC, Kuiken SD, et al. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J Viral Hepatitis. 2016;23:950–954. Epub ahead of print.
  • El-Khayat HR, Fouad YM, Maher M, et al. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut. 2017 Nov;66(11):2008-2012. Gutjnl −312012.
  • Waked I, Shiha G, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1(1):36–44.
  • Elbaz T, Elserafy M, Elakel W, et al. Serious adverse events with sofosbuvir combined with interferon and ribavirin: real-life Egyptian experience. J Interferon Cytokine Res. 2017;37(8):348–353.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.